206201-64-1

Basic information

• Product Name: 3-Pyridinecarbonitrile,6-formyl-(9CI)
• Synonyms: 3-Pyridinecarbonitrile,6-formyl-(9CI);6-Formyl-3-pyridinecarbonitrile
• CAS NO: 206201-64-1
• Molecular Formula: C₇H₄N₂O
• Molecular Weight: 132.12
• Product Categories: PYRIDINE
• Mol File: 206201-64-1.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 280.3±25.0 °C(Predicted)
• Appearance: /
• Density: 1.24±0.1 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 0.27±0.10(Predicted)
• CAS DataBase Reference: 3-Pyridinecarbonitrile,6-formyl-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Pyridinecarbonitrile,6-formyl-(9CI)(206201-64-1)
• EPA Substance Registry System: 3-Pyridinecarbonitrile,6-formyl-(9CI)(206201-64-1)

Safety Data

• Hazardous Substances Data: 206201-64-1(Hazardous Substances Data)

Usage

General Description

3-Pyridinecarbonitrile, 6-formyl-(9CI) is a chemical compound that belongs to the organic family of compounds known as pyridines and derivatives. The nitrile group on the 3-pyridinecarbonitrile gives it the potential to react under special conditions to form new compounds. The presence of the 6-formyl group can also be a site of reactivity. 3-Pyridinecarbonitrile,6-formyl-(9CI) is commonly used within chemical research and development due to the reactivity of these functional groups. Like all chemicals, it should be handled with care as its direct effects on human health or the environment are not entirely known. Molecular weight of 3-Pyridinecarbonitrile,6-formyl-(9CI) is 145.14 g/mol.

Upstream product

• 31795-61-6 6-(hydroxymethyl)pyridine-3-carbonitrile 
• 3222-48-8 6-methylnicotinonitrile 
• 16173-99-2 6-ethenylpyridine-3-carbonitrile 
• 1531599-37-7 (E)-6-[2-(dimethylamino)vinyl]nicotinonitrile 

Downstream Products

• 1097207-04-9 C₂₅H₂₄Cl₂N₄O₂ 
• 1427712-21-7 C₂₃H₂₀Cl₂N₄O 
• 170727-00-1 6-formylnicotinonitrile oxime 
• 1625672-29-8 1-((5-cyanopyridin-2-yl)(2-hydroxy-6-oxocyclohex-1-enyl)methyl)-3-(3-(trifluoromethyl)phenyl)urea 

Relevant articles and documents

ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF

The present invention relates to isoxazolidines of formula I and their use as receptor-interacting protein kinase 1 inhibitors, for example in the treatment of diseases and disorders mediated by RIP kinase (1) such as rheumatoid arthritis (RA), psoriasis, inflammatory bowel disease (IBD), Crohn's disease or ulcerative colitis.

Antiprotozoal activity of dicationic 3,5-diphenylisoxazoles, their prodrugs and aza-analogues

Fifty novel prodrugs and aza-analogues of 3,5-bis(4-amidinophenyl)isoxazole and its derivatives were prepared. Eighteen of the 24 aza-analogues exhibited IC50 values below 25 nM against Trypanosoma brucei rhodesiense or Plasmodium falciparum. S

SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS

Compounds of Formula (I) or pharmaceutically acceptable salts, solvates, or esters thereof, are useful in treating diseases or conditions mediated by CB1receptors, such as metabolic syndrome and obesity, neuroinflammatory disorders, cognitive disorders and psychosis, addiction (e.g., smoking cessation), gastrointestinal disorders, and cardiovascular conditions.